Top Markets
Coin of the day
Sanofi Sanofi

Sanofi

SNY
Classement en actions #178
Sanofi, together with its subsidiaries, engages in the research, development,... Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Prix de l'action
$44.60
Capitalisation boursière
$108.62B
Changement (1 jour)
-1.63%
Changement (1 an)
-21.62%
Pays
FR
Échange Sanofi (SNY)

Catégorie

Ratio P/E pour Sanofi (SNY)
Ratio P/E au March 2026 TTM : 8.78
Selon les derniers rapports financiers et le cours de l'action de Sanofi, le ratio P/E actuel (TTM) est de 8.78. À la fin de l’année 2024, le P/E de l’entreprise était de 21.10.
Historique du ratio P/E pour Sanofi de 2000 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
2026 (TTM) 8.78 -32.02%
2025 12.92 -38.76%
2024 21.10 1.40%
2023 20.81 54.85%
2022 13.44 -24.64%
2021 17.83 122.16%
2020 8.02 -79.90%
2019 39.92 82.18%
2018 21.91 -5.40%
2017 23.16 10.24%
2016 21.01 -12.27%
2015 23.95 5.61%
2014 22.68 -17.39%
2013 27.45 44.75%
2012 18.97 43.94%
2011 13.18 -8.09%
2010 14.34 4.92%
2009 13.66 65.17%
2008 8.27 -48.59%
2007 16.09 -32.21%
2006 23.74 -45.86%
2005 43.84 -317.87%
2004 -20.12 -199.40%
2003 20.24 -15.94%
2002 24.08 -37.41%
2001 38.47 -26.60%
2000 52.42 0.00%
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
42.86 388.04%
US
28.47 224.13%
GB
21.88 149.17%
US
92.55 953.80%
US
20.85 137.40%
CH
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.